Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Handovers During Anesthesia Care

Handovers During Anesthesia Care Editorial Opinion receptor antagonist, in patients with moderate 9. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. 15. Boyle PA, Wilson RS, Yu L, et al. Much of late life Alzheimer’s disease (LADDER): a randomised, Alzheimer’s disease drug development pipeline: 2017. cognitive decline is not due to common double-blind, placebo-controlled phase 2 trial. Alzheimers Dement (N Y). 2017;3(3):367-384. neurodegenerative pathologies. Ann Neurol. 2013; Lancet Neurol. 2014;13(11):1092-1099. 74(3):478-489. 10. Sloane PD, Zimmerman S, Suchindran C, et al. 4. Atri A, Frölich L, Ballard C, et al. Effect of The public health impact of Alzheimer’s disease, 16. National Institute on Aging. Accelerating idalopirdine as adjunct to cholinesterase inhibitors 2000-2050: potential implication of treatment Medicines Partnership—Alzheimer's Disease. on change in cognition in patients with Alzheimer advances. Annu Rev Public Health. 2002;23:213-231. https://www.nia.nih.gov/research/amp-ad. disease: three randomized clinical trials. JAMA. Accessed December 12, 2017. 11. Jack CR, Bennett DA, Blennow K, et al. 2018 doi:10.1001/jama.2017.20373 NIA-AA research framework to investigate the 17. Gaiteri C, Mostafavi S, Honey CJ, De Jager PL, 5. Biomedical Research Forum. Intepirdine Alzheimer’s disease continuum. https://alz.org/aaic Bennett DA. Genetic variants in Alzheimer disease: joins the ranks of failed Alzheimer’s drugs. /_downloads/draft-nia-aa-7-18-17.pdf. Accessed molecular and brain network approaches. Nat http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Handovers During Anesthesia Care

JAMA , Volume 319 (2) – Jan 9, 2018

Loading next page...
 
/lp/american-medical-association/handovers-during-anesthesia-care-ArRcETzAtm
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.20602
pmid
29318263
Publisher site
See Article on Publisher Site

Abstract

Editorial Opinion receptor antagonist, in patients with moderate 9. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. 15. Boyle PA, Wilson RS, Yu L, et al. Much of late life Alzheimer’s disease (LADDER): a randomised, Alzheimer’s disease drug development pipeline: 2017. cognitive decline is not due to common double-blind, placebo-controlled phase 2 trial. Alzheimers Dement (N Y). 2017;3(3):367-384. neurodegenerative pathologies. Ann Neurol. 2013; Lancet Neurol. 2014;13(11):1092-1099. 74(3):478-489. 10. Sloane PD, Zimmerman S, Suchindran C, et al. 4. Atri A, Frölich L, Ballard C, et al. Effect of The public health impact of Alzheimer’s disease, 16. National Institute on Aging. Accelerating idalopirdine as adjunct to cholinesterase inhibitors 2000-2050: potential implication of treatment Medicines Partnership—Alzheimer's Disease. on change in cognition in patients with Alzheimer advances. Annu Rev Public Health. 2002;23:213-231. https://www.nia.nih.gov/research/amp-ad. disease: three randomized clinical trials. JAMA. Accessed December 12, 2017. 11. Jack CR, Bennett DA, Blennow K, et al. 2018 doi:10.1001/jama.2017.20373 NIA-AA research framework to investigate the 17. Gaiteri C, Mostafavi S, Honey CJ, De Jager PL, 5. Biomedical Research Forum. Intepirdine Alzheimer’s disease continuum. https://alz.org/aaic Bennett DA. Genetic variants in Alzheimer disease: joins the ranks of failed Alzheimer’s drugs. /_downloads/draft-nia-aa-7-18-17.pdf. Accessed molecular and brain network approaches. Nat

Journal

JAMAAmerican Medical Association

Published: Jan 9, 2018

References